



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

			www.uspto.gov	
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	COLUMN
10/618,526	07/11/2003	Frits Jacobus Fallaux	2578-3833. 9US	CONFIRMATION NO.
24247	7590 04/06/2005		2070 3033. 703	5055
TRASK BRITT			EXAMINER	
P.O. BOX 255	60		NGUYEN, DA	VE TRONG
SALT LAKE	CITY, UT 84110		ART UNIT PAPER NUMBER	
			1632	
			DATE MAILED: 04/06/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
		10/618,526	FALLAUX ET AL.			
Office Action Summary		Examiner	Art Unit			
		Dave T. Nguyen	1632			
	The MAILING DATE of this communication app	pears on the cover sheet with the	Correspondence address			
	or Reply					
- Extended after a	MORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Pensions of time may be available under the provisions of 37 CFR 1.13 or SIX (6) MONTHS from the mailing date of this communication. Pe period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we pure to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be within the statutory minimum of thirty (30) drill apply and will expire SIX (6) MONTHS fro	timely filed ays will be considered timely. m the mailing date of this communication.			
Status						
1)🖂	Responsive to communication(s) filed on 28 Fe	hruary 2005				
	Pa)⊠ This action is FINAL . 2b)□ This action is non-final.					
	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disnositi	ion of Claims	r parto quayro, 1000 C.D. 11, 4	65 O.G. 215.			
	•					
4)[2]	4) Claim(s) <u>1,3-7,9-12,14-16 and 18-28</u> is/are pending in the application.					
E\[\	4a) Of the above claim(s) is/are withdrawn from consideration.					
	Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1, 3-7, 9-12, 14-16, 18-28</u> is/are rejected.						
	Claim(s) is/are objected to.					
8)[Claim(s) are subject to restriction and/or	election requirement.				
Applicati	on Papers					
9) 🗌 :	The specification is objected to by the Examiner.					
10)	The drawing(s) filed on is/are: a) accept	oted or b) abjected to but be	For which			
•	Applicant may not request that any objection to the dr	caving(s) he held in above as a	Examiner.			
	Replacement drawing sheet(s) including the correction	n is required if the drawing (1) is a	e 37 CFR 1.85(a).			
11) 🔲 🗀	Replacement drawing sheet(s) including the correction The oath or declaration is objected to by the Exa	minor Note the attacked Office	Jected to. See 37 CFR 1.121(d).			
		miner. Note the attached Office	Action or form PTO-152.			
Priority u	nder 35 U.S.C. § 119	•	,			
12) 🗌 A	Acknowledgment is made of a claim for foreign p	riority under 35 U.S.C. & 119/a)-(d) or (f)			
a)[☐ All b)☐ Some * c)☐ None of:	3(4)	, (3) 3. (1).			
	 Certified copies of the priority documents I 	have been received.	•			
2. Certified copies of the priority documents have been received in Application No						
;	3. Copies of the certified copies of the priority	documents have been receive	ed in this National Stage			
	application from the International Bureau (PCT Rule 17.2(a)).	or in the National Stage			
* Se	ee the attached detailed Office action for a list of	the certified copies not receive	d.			
ttachment(·					
) Notice	of References Cited (PTO-892)	4) 🔀 Interview Summary	(PTO-413)			
) Informa	of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	Paper No(s)/Mail Da	te			
Paper	No(s)/Mail Date	6) Other:	atent Application (PTO-152)			
Patent and Trac OL-326 (Rev	4.4.0					
(1161	0. 1-04) Office Action	n Summary D.	art of Paner No /Mail Date 4012005			

Application/Control Number: 10/618,526

Art Unit: 1632

Claims 1, 3-7, 9-12, 14-16, 18-28 have been amended; and claims 2, 8, 13, and 17 have been canceled by the amendment filed February 24, 2005.

The terminal disclaimer with respect to Pat No. 5,994,128 has been entered.

The signed Declaration regarding the compliance of the deposit rules with respect to the PER.C6 cell line has been entered.

The examiner acknowledges the personal interview with applicants on Feb. 8, 2005, and the discussion regarding the interview is correct.

As the result of the claimed amendment, all rejections under 35 USC 112, first paragraph are withdrawn by the examiner.

The prior art rejections are also withdrawn by the examiner because of the prior art of record, e.g., Imler, Wilson, Graham, do not teach an isolated adenovirus packaging cell, wherein its genome comprises a first nucleic acid sequence encoding E1A and E1B gene products; but lacks a nucleic acid sequence encoding adenovirus pIX.

Claims 1, 3-7, 9-12, 14-16, 18-28, to which the remaining grounds of rejection remain applicable are pending.

Double Patenting Rejection

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA

Application/Control Number: 10/618,526

Art Unit: 1632

1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1, 3-7, 9-12, 14-16, 18-28 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over any of claims 1-14 of US Pat No. 6,033,908, claims 1-5 of US Pat No. 6,265,212, claims 1-14 of US Pat 6,306,652, or claims 1-12 of US Pat No. 6,692,966.

The claims are obvious variants because all set of claims encompass the make and use of:

A packaging cell for production of replication defective adenovirus vectors comprising a packaging construct comprising nucleotides 459-3510 of a human adenovirus 5 genome wherein said cell lacks an adenovirus gene coding for functionally active pIX gene products, and wherein said cell comprises nucleic acid sequences coding for functionally active E1A and E1B gene products under the control of a promoter.

Thus, the patent claims and the application claims are obvious variant of one another.

Application/Control Number: 10/618,526

Art Unit: 1632

Claims 1, 3-7, 9-12, 14-16, 18-28 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over any of claims 26-34 of US Application 10/125,751, and claims 21, 9, and 10 of US Application No. 10/219,414.

The claims are obvious variants because all set of claims encompass the make and use of:

A packaging cell for production of replication defective adenovirus vectors comprising a packaging construct comprising nucleotides 459-3510 of a human adenovirus 5 genome, wherein said construct lacks an adenovirus gene coding for functionally active pIX gene products, and wherein said construct comprises nucleic acid sequences coding for functionally active E1A and E1B gene products under the control of a promoter.

Thus, the patent claims and the application claims are obvious variant of one another.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

No claims are allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within

Art Unit: 1632

TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner *Dave Nguyen* whose telephone number is **571-272-0731**.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, *Ram Shukla*, may be reached at **571-272-0735**.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Central Fax number, which is **571-273-8300**.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Art Unit: 1632

Dave Nguyen
Primary Examiner

PRIMARY EXAMINER